null

FITC Anti-Human CD326 Antibody [9C4] (AGEL1819)

SKU:
AGEL1819
Product Type:
Antibody
Antibody Type:
Monoclonal Antibody
Reactivity:
Human
Applications:
FC
$227 - $875
Frequently bought together:

Description

system_update_altDatasheetsystem_update_altMSDS

FITC Anti-Human CD326 Antibody [9C4]

The Human CD326 Monoclonal Antibody (FITC Conjugated 9C4) is a cutting-edge tool designed for researchers studying CD326, a key cell surface marker involved in various cellular processes. This high-quality antibody, carefully developed and validated by Assay Genie, offers exceptional specificity and sensitivity for detecting CD326 in human samples, making it an invaluable asset in a wide range of research applications.CD326, also known as EpCAM, is a transmembrane glycoprotein with important implications in cell adhesion and signaling. Its involvement in processes such as proliferation, differentiation, and migration renders it a fascinating target for investigations spanning fields like stem cell biology, cancer research, and developmental biology. By targeting CD326 with this monoclonal antibody, researchers can effectively study its expression, localization, and function in diverse cell types and experimental contexts.

With its FITC conjugation, the 9C4 monoclonal antibody allows for easy and efficient fluorescent detection of CD326, facilitating precise localization and quantification of the protein within cells or tissues. This feature expands the utility of the antibody in flow cytometry, immunofluorescence, and other imaging techniques, enabling researchers to gain deeper insights into the roles played by CD326 in normal physiology and disease states.In conclusion, the Human CD326 Monoclonal Antibody (FITC Conjugated 9C4) from Assay Genie represents a valuable resource for scientists interested in unraveling the complexities of CD326 biology. Its reliability, specificity, and versatility make it a potent tool for driving forward our understanding of cellular dynamics and disease mechanisms, paving the way for innovative discoveries and therapeutic advancements.